Trial · NCT02246673
Adverse events69
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 69
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dyspepsia | Gastrointestinal disorders | Febuxostat 40 mg | 1 | 61 | 1 |
| other | Dyspepsia | Gastrointestinal disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Dyspepsia | Gastrointestinal disorders | Overall RDEA3170 + Febuxostat Combination | 2 | 62 | 2 |
| other | Aphthous Stomatitis | Gastrointestinal disorders | Febuxostat 40 mg | 0 | 61 | 0 |
| other | Aphthous Stomatitis | Gastrointestinal disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Aphthous Stomatitis | Gastrointestinal disorders | Overall RDEA3170 + Febuxostat Combination | 1 | 62 | 2 |
| other | Constipation | Gastrointestinal disorders | Febuxostat 40 mg | 1 | 61 | 1 |
| other | Constipation | Gastrointestinal disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Constipation | Gastrointestinal disorders | Overall RDEA3170 + Febuxostat Combination | 0 | 62 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat 40 mg | 0 | 61 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Diarrhoea | Gastrointestinal disorders | Overall RDEA3170 + Febuxostat Combination | 1 | 62 | 1 |
| other | Pain In Extremity | Musculoskeletal and connective tissue disorders | Febuxostat 40 mg | 0 | 61 | 0 |
| other | Pain In Extremity | Musculoskeletal and connective tissue disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Pain In Extremity | Musculoskeletal and connective tissue disorders | Overall RDEA3170 + Febuxostat Combination | 3 | 62 | 3 |
| other | Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | Febuxostat 40 mg | 0 | 61 | 0 |
| other | Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | Febuxostat 80 mg | 0 | 51 | 0 |
| other | Musculoskeletal Pain | Musculoskeletal and connective tissue disorders | Overall RDEA3170 + Febuxostat Combination | 2 | 62 | 2 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Febuxostat 40 mg | 0 | 61 | 0 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Febuxostat 80 mg | 0 | 51 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02246673/events